Natural products for drug discovery in the 21st century: Innovations for novel drug discovery

International Journal of Molecular Sciences

Volumn 19, Issue 6, 2018, Pages

  Thomford, Nicholas Ekow ^a,b   Senthebane, Dimakatso Alice ^a,c   Rowe, Arielle ^c   Munro, Daniella ^a   Seele, Palesa ^a   Maroyi, Alfred ^d   Dzobo, Kevin ^a,c  

^a UNIVERSITY OF CAPE TOWN   (South Africa)

^b UNIVERSITY OF CAPE COAST   (Ghana)

^c UNIVERSITY OF CAPE TOWN   (South Africa)

^d UNIVERSITY OF FORT HARE   (South Africa)

Author keywords

Automation; Bioinformatics; Computational softwares; Drug design and development; Global health; Innovation; Natural products; Omics; Precisionmedicine

Indexed keywords

BIOLOGICAL MARKER; NATURAL PRODUCT; PLANT EXTRACT; BIOLOGICAL PRODUCT;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ARTIFICIAL INTELLIGENCE; AUTOMATION; BIOINFORMATICS; DEGENERATIVE DISEASE; DIABETES MELLITUS; DRUG DESIGN; GLOBAL HEALTH; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; MICROFLUIDIC ANALYSIS; MOLECULAR INTERACTION; NONHUMAN; PERSONALIZED MEDICINE; PROTEIN FUNCTION; PROTEOMICS; REVIEW; WHOLE GENOME SEQUENCING; BIOLOGY; CHEMICAL MODEL; CHEMISTRY; COMPUTER SIMULATION; DRUG DEVELOPMENT; DRUG INDUSTRY; LABORATORY AUTOMATION; MEDICINAL PLANT; PHYTOTHERAPY; PROCEDURES; ROBOTICS; SOFTWARE;

ARTIFICIAL INTELLIGENCE; AUTOMATION, LABORATORY; BIOLOGICAL PRODUCTS; COMPUTATIONAL BIOLOGY; COMPUTER SIMULATION; DRUG DESIGN; DRUG DISCOVERY; DRUG INDUSTRY; HUMANS; MODELS, CHEMICAL; PHYTOTHERAPY; PLANTS, MEDICINAL; ROBOTICS; SOFTWARE;

EID: 85047725344     PISSN: 16616596     EISSN: 14220067     Source Type: Journal    
DOI: 10.3390/ijms19061578     Document Type: Review

References (307)

1. Weng, J.K.; Philippe, R.N.; Noel, J.P. The rise of chemodiversity in plants. Science 2012, 336, 1667-1670.
2. Lietava, J. Medicinal plants in a Middle Paleolithic grave Shanidar IV? J. Ethnopharmacol. 1992, 35, 263-266.
3. Ernst, M.; Grace, O.M.; Saslis-Lagoudakis, C.H.; Nilsson, N.; Simonsen, H.T.; Ronsted, N. Global medicinal uses of Euphorbia L. (Euphorbiaceae). J. Ethnopharmacol. 2015, 176, 90-101.
4. Gozubuyuk, G.S.; Aktas, E.; Yigit, N. An ancient plant Lawsonia inermis (henna): Determination of in vitro antifungal activity against dermatophytes species. J. Mycol. Med. 2014, 24, 313-318.
5. Hotwani, K.; Baliga, S.; Sharma, K. Phytodentistry: Use of medicinal plants. J. Complement. Integr. Med. 2014, 11, 233-251.
6. Liu, Q.; Lawrence, A.J.; Liang, J.H. Traditional Chinese medicine for treatment of alcoholism: From ancient to modern. Am. J. Chin. Med. 2011, 39, 1-13.
7. Mannangatti, P.; Naidu, K.N. Indian herbs for the treatment of neurodegenerative disease. Adv. Neurobiol. 2016, 12, 323-336.
8. McGovern, P.E.; Mirzoian, A.; Hall, G.R. Ancient Egyptian herbal wines. Proc. Natl. Acad. Sci. USA 2009, 106, 7361-7366.
9. Blunt, J.W.; Carroll, A.R.; Copp, B.R.; Davis, R.A.; Keyzers, R.A.; Prinsep, M.R. Marine natural products. Nat. Prod. Rep. 2018, 35, 8-53.
10. Harvey, A.L. Natural products in drug discovery. Drug Discov. Today 2008, 13, 894-901.
11. Harvey, A.L.; Clark, R.L.; Mackay, S.P.; Johnston, B.F. Current strategies for drug discovery through natural products. Expert Opin. Drug Discov. 2010, 5, 559-568.
12. Harvey, A.L.; Edrada-Ebel, R.; Quinn, R.J. The re-emergence of natural products for drug discovery in the genomics era. Nat. Rev. Drug Discov. 2015, 14, 111-129.
13. Chang, J.; Kim, Y.; Kwon, H.J. Advances in identification and validation of protein targets of natural products without chemical modification. Nat. Prod. Rep. 2016, 33, 719-730.
14. Tansaz, M.; Tajadini, H. Comparison of leiomyoma of modern medicine and traditional Persian medicine. J. Evid.-Based Complement. Altern. Med. 2016, 21, 160-163.
15. Xu, Q.; Bauer, R.; Hendry, B.M.; Fan, T.P.; Zhao, Z.; Duez, P.; Simmonds, M.S.;Witt, C.M.; Lu, A.; Robinson, N.; et al. The quest for modernisation of traditional Chinese medicine. BMC Complement. Altern. Med. 2013, 13, 132.
16. Yuan, H.; Ma, Q.; Ye, L.; Piao, G. The traditional medicine and modern medicine from natural products. Molecules 2016, 21, 559.
17. Banjari, I.; Misir, A.; Savikin, K.; Jokic, S.; Molnar, M.; De Zoysa, H.K.S.; Waisundara, V.Y. Antidiabetic effects of Aronia melanocarpa and its other therapeutic properties. Front. Nutr. 2017, 4, 53.
18. Yatoo, M.I.; Dimri, U.; Gopalakrishnan, A.; Karthik, K.; Gopi, M.; Khandia, R.; Saminathan, M.; Saxena, A.; Alagawany, M.; Farag, M.R.; et al. Beneficial health applications and medicinal values of pedicularis plants:A review. Biomed. Pharmacother. 2017, 95, 1301-1313.
19. Thomford, N.E.; Awortwe, C.; Dzobo, K.; Adu, F.; Chopera, D.; Wonkam, A.; Skelton, M.; Blackhurst, D.; Dandara, C. Inhibition of cyp2b6 by medicinal plant extracts: Implication for use of efavirenz and nevirapine-based highly active anti-retroviral therapy (HAART) in resource-limited settings. Molecules 2016, 21, 211.
20. Thomford, N.E.; Dzobo, K.; Chopera, D.; Wonkam, A.; Maroyi, A.; Blackhurst, D.; Dandara, C. In vitro reversible and time-dependent cyp450 inhibition profiles of medicinal herbal plant extracts Newbouldia laevis and Cassia abbreviata: Implications for herb-drug interactions. Molecules 2016, 21, 891.
21. Thomford, N.E.; Dzobo, K.; Chopera, D.; Wonkam, A.; Skelton, M.; Blackhurst, D.; Chirikure, S.; Dandara, C. Pharmacogenomics implications of using herbal medicinal plants on African populations in health transition. Pharmaceuticals 2015, 8, 637-663.
22. Thomford, N.E.; Mkhize, B.; Dzobo, K.; Mpye, K.; Rowe, A.; Parker, M.I.; Wonkam, A.; Skelton, M.; September, A.V.; Dandara, C. African lettuce (Launaea taraxacifolia) displays possible anticancer effects and herb-drug interaction potential by CYP1A2, CYP2C9, and CYP2C19 inhibition. Omics 2016, 20, 528-537.
23. Ji, S.; Fattahi, A.; Raffel, N.; Hoffmann, I.; Beckmann, M.W.; Dittrich, R.; Schrauder, M. Antioxidant effect of aqueous extract of four plants with therapeutic potential on gynecological diseases; semen persicae, Leonurus cardiaca, Hedyotis diffusa, and Curcuma zedoaria. Eur. J. Med. Res. 2017, 22, 50.
24. Ruhsam, M.; Hollingsworth, P.M. Authentication of eleutherococcus and rhodiola herbal supplement products in the United Kingdom. J. Pharm. Biomed. Anal. 2017, 149, 403-409.
25. Patridge, E.; Gareiss, P.; Kinch, M.S.; Hoyer, D. An analysis of FDA-approved drugs: Natural products and their derivatives. Drug Discov. Today 2016, 21, 204-207.
26. Wani, M.C.; Taylor, H.L.; Wall, M.E.; Coggon, P.; McPhail, A.T. Plant antitumor agents. VI. The isolation and structure of taxol, a novel antileukemic and antitumor agent from Taxus brevifolia. J. Am. Chem. Soc. 1971, 93, 2325-2327.
27. Newman, D.J.; Cragg, G.M. Natural products as sources of new drugs over the 30 years from 1981 to 2010. J. Nat. Prod. 2012, 75, 311-335.
28. Carter, G.T. Natural products and Pharma 2011: Strategic changes spur new opportunities. Nat. Prod. Rep. 2011, 28, 1783-1789.
29. Li, J.W.; Vederas, J.C. Drug discovery and natural products: End of an era or an endless frontier? Science 2009, 325, 161-165.
30. Li, F.S.; Weng, J.K. Demystifying traditional herbal medicine with modern approach. Nat. Plants 2017, 3, 17109.
31. Kiyohara, H.; Matsumoto, T.; Yamada, H. Combination effects of herbs in a multi-herbal formula: Expression of juzen-taiho-to’s immuno-modulatory activity on the intestinal immune system. Evid.-Based Complement. Altern. Med. 2004, 1, 83-91.
32. Leonti, M.; Verpoorte, R. Traditional Mediterranean and European herbal medicines. J. Ethnopharmacol. 2017, 199, 161-167.
33. Ozdemir, V.; Hekim, N. Birth of industry 5.0: Making sense of big data with artificial intelligence, “the internet of things” and next-generation technology policy. Omics 2018, 22, 65-76.
34. Özdemir, V. Omics 2.0: An accelerator for global science, systems medicine and responsible innovation. Omics 2015, 19, 579-580.
35. Wall, M.E.; Wani, M.C.; Brown, D.M.; Fullas, F.; Olwald, J.B.; Josephson, F.F.; Thornton, N.M.; Pezzuto, J.M.; Beecher, C.W.; Farnsworth, N.R.; et al. Effect of tannins on screening of plant extracts for enzyme inhibitory activity and techniques for their removal. Phytomedicine 1996, 3, 281-285.
36. Eldridge, G.R.; Vervoort, H.C.; Lee, C.M.; Cremin, P.A.; Williams, C.T.; Hart, S.M.; Goering, M.G.; O’Neil-Johnson, M.; Zeng, L. High-throughput method for the production and analysis of large natural product libraries for drug discovery. Anal. Chem. 2002, 74, 3963-3971.
37. Wu, S.; Liang, J. Counter-current chromatography for high throughput analysis of natural products. Comb. Chem. High Throughput Screen. 2010, 13, 932-942.
38. Bugni, T.S.; Richards, B.; Bhoite, L.; Cimbora, D.; Harper, M.K.; Ireland, C.M. Marine natural product libraries for high-throughput screening and rapid drug discovery. J. Nat. Prod. 2008, 71, 1095-1098.
39. Koehn, F.E. High impact technologies for natural products screening. In Natural Compounds as Drugs Volume I; Birkhäuser: Basel, Switzerland, 2008; Volume 65, pp. 175-210.
40. Wong, W.R.; Oliver, A.G.; Linington, R.G. Development of antibiotic activity profile screening for the classification and discovery of natural product antibiotics. Chem. Biol. 2012, 19, 1483-1495.
41. He, G.; Yin, Y.; Yan, X.;Wang, Y. Semi-bionic extraction of effective ingredient from fishbone by high intensity pulsed electric fields. J. Food Process Eng. 2017, 40, e12392.
42. Yoshioka, T.; Nagatomi, Y.; Harayama, K.; Bamba, T. Development of an analytical method for polycyclic aromatic hydrocarbons in coffee beverages and dark beer using novel high-sensitivity technique of supercritical fluid chromatography/mass spectrometry. J. Biosci. Bioeng. 2018.
43. Hofstetter, R.; Fassauer, G.M.; Link, A. Supercritical fluid extraction (SFE) of ketamine metabolites from dried urine and on-line quantification by supercritical fluid chromatography and single mass detection (on-line SFE-SFC-MS). J. Chromatogr. B 2018, 1076, 77-83.
44. Morales, D.; Piris, A.J.; Ruiz-Rodriguez, A.; Prodanov, M.; Soler-Rivas, C. Extraction of bioactive compounds against cardiovascular diseases from Lentinula edodes using a sequential extraction method. Biotechnol. Prog. 2018.
45. Joana Gil-Chávez, G.; Villa, J.A.; Fernando Ayala-Zavala, J.; Basilio Heredia, J.; Sepulveda, D.; Yahia, E.M.; González-Aguilar, G.A. Technologies for extraction and production of bioactive compounds to be used as nutraceuticals and food ingredients: An overview. Compr. Rev. Food Sci. Food Saf. 2013, 12, 5-23.
46. De Morais, S.R.; Oliveira, T.L.; de Oliveira, L.P.; Tresvenzol, L.M.; da Conceicao, E.C.; Rezende, M.H.; Fiuza, T.S.; Costa, E.A.; Ferri, P.H.; de Paula, J.R. Essential oil composition, antimicrobial and pharmacological activities of Lippia sidoides cham. (verbenaceae) from Sao Goncalo do Abaete, Minas Gerais, Brazil. Pharmacogn. Mag. 2016, 12, 262-270. [PubMed]
47. Gan, Z.; Liang, Z.; Chen, X.;Wen, X.;Wang, Y.; Li, M.; Ni, Y. Separation and preparation of 6-gingerol from molecular distillation residue of Yunnan ginger rhizomes by high-speed counter-current chromatography and the antioxidant activity of ginger oils in vitro. J. Chromatogr. B Anal. Technol. Biomed. Life Sci. 2016, 1011, 99-107.
48. Zhang, L.; Mei, J.; Xie, Y.; Li, M.; Liu, D.; He, C. Application of membrane separation technology in extraction process of Chuanxiong Chatiao granules. Zhongguo Zhong yao za zhi = Zhongguo zhongyao zazhi = China J. Chin. Mater. Med. 2012, 37, 934-936.
49. Williams, S.; Oatley, D.; Abdrahman, A.; Butt, T.; Nash, R. Membrane technology for the improved separation of bioactive compounds. Procedia Eng. 2012, 44, 2112-2114.
50. Wang, H.; Jiang, Y.; Ding, M.; Li, J.; Hao, J.; He, J.; Wang, H.; Gao, X.M.; Chang, Y.X. Simultaneous determination and qualitative analysis of six types of components in Naoxintong capsule by miniaturized matrix solid-phase dispersion extraction coupled with ultra high-performance liquid chromatography with photodiode array detection and quadrupole time-of-flight mass spectrometry. J. Sep. Sci. 2018.
51. Zhang, L.; Ge, Y.; Li, J.; Hao, J.; Wang, H.; He, J.; Gao, X.M.; Chang, Y.X. Simultaneous determination of columbianetin-beta-d-glucopyranoside and columbianetin in a biological sample by high-performance liquid chromatography with fluorescence detection and identification of other columbianetin-beta-d-glucopyranoside metabolites by ultra high-performance liquid chromatography coupled with quadrupole-time of flight mass spectrometry. J. Pharm. Biomed. Anal. 2018, 153, 221-231.
52. Manglik, A.; Kruse, A.C.; Kobilka, T.S.; Thian, F.S.; Mathiesen, J.M.; Sunahara, R.K.; Pardo, L.; Weis, W.I.; Kobilka, B.K.; Granier, S. Crystal structure of the micro-opioid receptor bound to a morphinan antagonist. Nature 2012, 485, 321-326.
53. Edwards, G. Forces of habit: Drugs and the making of the modern world. Addiction 2002, 97, 608-609.
54. Zhao, L.; Li, C.; Zhang, Y.;Wen, Q.; Ren, D. Phytochemical and biological activities of an anticancer plant medicine: Brucea javanica. Anti-Cancer Agents Med. Chem. 2014, 14, 440-458.
55. Tu, Y. The discovery of artemisinin (qinghaosu) and gifts from Chinese medicine. Nat. Med. 2011, 17, 1217-1220.
56. Tu, Y. Artemisinin-A gift from traditional Chinese medicine to the world (Nobel lecture). Angew. Chem. Int. Ed. Engl. 2016, 55, 10210-10226.
57. Li, J.; Casteels, T.; Frogne, T.; Ingvorsen, C.; Honoré, C.; Courtney, M.; Huber, K.V.M.; Schmitner, N.; Kimmel, R.A.; Romanov, R.A.; et al. Artemisinins target GABAA receptor signaling and impair α cell identity. Cell 2017, 168, 86-100.
58. Lai, H.; Singh, N.P. Oral artemisinin prevents and delays the development of 7,12-dimethylbenz[a]anthracene (dmba)-induced breast cancer in the rat. Cancer Lett. 2006, 231, 43-48.
59. Lai, H.C.; Singh, N.P.; Sasaki, T. Development of artemisinin compounds for cancer treatment. Investig. New Drugs 2013, 31, 230-246.
60. Return to Rio: Second chance for the planet. Nature 2012, 486, 19.
61. Barbault, R. 2010: A new beginning for biodiversity? C.R. Biol. 2011, 334, 483-488.
62. Salazar, R.; Cabrera, J.A. Intellectual property rights in Costa Rica in the light of the biodiversity convention. J. Ethnopharmacol. 1996, 51, 177-193.
63. Samper, C. Taxonomy and environmental policy. Philos. Trans. R. Soc. Lond. B Biol. Sci. 2004, 359, 721-728.
64. Seidl, P.R. Pharmaceuticals from natural products: Current trends. Anais da Academia Brasileira de Ciencias 2002, 74, 145-150.
65. Tollefson, J.; Gilbert, N. Earth summit: Rio report card. Nature 2012, 486, 20-23.
66. Wen, M.C.;Wei, C.H.; Hu, Z.Q.; Srivastava, K.; Ko, J.; Xi, S.T.; Mu, D.Z.; Du, J.B.; Li, G.H.;Wallenstein, S.; et al. Efficacy and tolerability of anti-asthma herbal medicine intervention in adult patients with moderate-severe allergic asthma. J. Allergy Clin. Immunol. 2005, 116, 517-524.
67. Srivastava, K.; Sampson, H.A.; Charles, W.; Emala, S.; Li, X.-M. The anti-asthma herbal medicine ashmi acutely inhibits airway smooth muscle contraction via prostaglandin e2 activation of ep2/ep4 receptors. Am. J. Physiol.-Lung Cell. Mol. Physiol. 2013, 305, L1002-L1010.
68. Yang, N.; Liang, B.; Srivastava, K.; Zeng, J.; Zhan, J.; Brown, L.; Sampson, H.; Goldfarb, J.; Emala, C.; Li, X.M. The Sophora flavescens flavonoid compound trifolirhizin inhibits acetylcholine induced airway smooth muscle contraction. Phytochemistry 2013, 95, 259-267.
69. Chan, K.; Shaw, D.; Simmonds, M.S.; Leon, C.J.; Xu, Q.; Lu, A.; Sutherland, I.; Ignatova, S.; Zhu, Y.P.; Verpoorte, R.; et al. Good practice in reviewing and publishing studies on herbal medicine, with special emphasis on traditional Chinese medicine and Chinese materia medica. J. Ethnopharmacol. 2012, 140, 469-475.
70. Skroza, D.; Generalić Mekinić, I.; Svilović, S.; Šimat, V.; Katalinić, V. Investigation of the potential synergistic effect of resveratrol with other phenolic compounds: A case of binary phenolic mixtures. J. Food Compos. Anal. 2015, 38, 13-18.
71. Chusri, S.; Siriyong, T.; Na-Phatthalung, P.; Voravuthikunchai, S.P. Synergistic effects of ethnomedicinal plants of Apocynaceae family and antibiotics against clinical isolates of Acinetobacter baumannii. Asian Pac. J. Trop. Med. 2014, 7, 456-461.
72. Sharma, G.; Tyagi, A.K.; Singh, R.P.; Chan, D.C.; Agarwal, R. Synergistic anti-cancer effects of grape seed extract and conventional cytotoxic agent doxorubicin against human breast carcinoma cells. Breast Cancer Res. Treat. 2004, 85, 1-12.
73. Medema, M.H.; Fischbach, M.A. Computational approaches to natural product discovery. Nat. Chem. Biol. 2015, 11, 639-648.
74. Kim, E.; Moore, B.S.; Yoon, Y.J. Reinvigorating natural product combinatorial biosynthesis with synthetic biology. Nat. Chem. Biol. 2015, 11, 649-659.
75. Akbulut, Y.; Gaunt, H.J.; Muraki, K.; Ludlow, M.J.; Amer, M.S.; Bruns, A.; Vasudev, N.S.; Radtke, L.;Willot, M.; Hahn, S.; et al. (-)-Englerin A is a potent and selective activator of TRPC4 and TRPC5 calcium channels. Angew. Chem. Int. Ed. Engl. 2015, 54, 3787-3791.
76. +-atpase. J. Biol. Chem. 2017, 292, 723-731.
77. +) entry through heteromeric TRPC4/C1 channels mediates (-)Englerin A-induced cytotoxicity in synovial sarcoma cells. Sci. Rep. 2017, 7, 16988.
78. Buriani, A.; Garcia-Bermejo, M.L.; Bosisio, E.; Xu, Q.; Li, H.; Dong, X.; Simmonds, M.S.; Carrara, M.; Tejedor, N.; Lucio-Cazana, J.; et al. Omic techniques in systems biology approaches to traditional Chinese medicine research: Present and future. J. Ethnopharmacol. 2012, 140, 535-544.
79. Ganie, S.H.; Upadhyay, P.; Das, S.; Prasad Sharma, M. Authentication of medicinal plants by DNA markers. Plant Gene 2015, 4, 83-99.
80. Ghorbani, A.; Saeedi, Y.; de Boer, H.J. Unidentifiable by morphology: DNA barcoding of plant material in local markets in Iran. PLoS ONE 2017, 12, e0175722.
81. Thompson, K.A.; Newmaster, S.G. Molecular taxonomic tools provide more accurate estimates of species richness at less cost than traditional morphology-based taxonomic practices in a vegetation survey. Biodivers. Conserv. 2014, 23, 1411-1424.
82. Cao, M.; Wang, J.; Yao, L.; Xie, S.; Du, J.; Zhao, X. Authentication of animal signatures in traditional Chinese medicine of Lingyang Qingfei Wan using routine molecular diagnostic assays. Mol. Biol. Rep. 2014, 41, 2485-2491.
83. Newmaster, S.G.; Grguric, M.; Shanmughanandhan, D.; Ramalingam, S.; Ragupathy, S. DNA barcoding detects contamination and substitution in North American herbal products. BMC Med. 2013, 11, 222.
84. Mishra, P.; Kumar, A.; Nagireddy, A.; Mani, D.N.; Shukla, A.K.; Tiwari, R.; Sundaresan, V. DNA barcoding:An efficient tool to overcome authentication challenges in the herbal market. Plant Biotechnol. J. 2016, 14, 8-21.
85. Chen, X.; Xiang, L.; Shi, L.; Li, G.; Yao, H.; Han, J.; Lin, Y.; Song, J.; Chen, S. Identification of crude drugs in the Japanese pharmacopoeia using a DNA barcoding system. Sci. Rep. 2017, 7, 42325.
86. Pulice, G.; Pelaz, S.; Matías-Hernández, L. Molecular farming in Artemisia annua, a promising approach to improve anti-malarial drug production. Front. Plant Sci. 2016, 7, 329.
87. Gantait, S.; Debnath, S.; Nasim Ali, M. Genomic profile of the plants with pharmaceutical value. 3 Biotech 2014, 4, 563-578.
88. Lv, C.; Wu, X.; Wang, X.; Su, J.; Zeng, H.; Zhao, J.; Lin, S.; Liu, R.; Li, H.; Li, X.; et al. The gene expression profiles in response to 102 traditional Chinese medicine (TCM) components: A general template for research on TCMs. Sci. Rep. 2017, 7, 352.
89. Lee, K.-H.; Lo, H.-L.; Tang,W.-C.; Hsiao, H.H.-Y.; Yang, P.-M. A gene expression signature-based approach reveals the mechanisms of action of the Chinese herbal medicine Berberine. Sci. Rep. 2014, 4, 6394.
90. Kiyama, R. DNA microarray-based screening and characterization of traditional Chinese medicine. Microarrays 2017, 6, 4.
91. Jones, M.J.; Goodman, S.J.; Kobor, M.S. DNA methylation and healthy human aging. Aging Cell 2015, 14, 924-932.
92. Kelly, T.K.; Liu, Y.; Lay, F.D.; Liang, G.; Berman, B.P.; Jones, P.A. Genome-wide mapping of nucleosome positioning and DNA methylation within individual DNA molecules. Genome Res. 2012, 22, 2497-2506.
93. Nordlund, J.; Backlin, C.L.;Wahlberg, P.; Busche, S.; Berglund, E.C.; Eloranta, M.L.; Flaegstad, T.; Forestier, E.; Frost, B.M.; Harila-Saari, A.; et al. Genome-wide signatures of differential DNA methylation in pediatric acute lymphoblastic leukemia. Genome Biol. 2013, 14, r105.
94. Su, J.;Wang, Y.; Xing, X.; Liu, J.; Zhang, Y. Genome-wide analysis of DNA methylation in bovine placentas. BMC Genom. 2014, 15, 12.
95. Zykovich, A.; Hubbard, A.; Flynn, J.M.; Tarnopolsky, M.; Fraga, M.F.; Kerksick, C.; Ogborn, D.; MacNeil, L.; Mooney, S.D.; Melov, S. Genome-wide DNA methylation changes with age in disease-free human skeletal muscle. Aging Cell 2014, 13, 360-366.
96. Barbosa, S.; Carreira, S.; Bailey, D.; Abaitua, F.; O’Hare, P. Phosphorylation and SCF-mediated degradation regulate CREB-H transcription of metabolic targets. Mol. Biol. Cell 2015, 26, 2939-2954.
97. Bose, P.; Vachhani, P.; Cortes, J.E. Treatment of relapsed/refractory acute myeloid leukemia. Curr. Treat. Options Oncol. 2017, 18, 17.
98. Ley, T.J.; Miller, C.; Ding, L.; Raphael, B.J.; Mungall, A.J.; Robertson, A.; Hoadley, K.; Triche, T.J., Jr.; Laird, P.W.; Baty, J.D.; et al. Genomic and epigenomic landscapes of adult de novo acute myeloid leukemia. N. Engl. J. Med. 2013, 368, 2059-2074. [PubMed]
99. Brat, D.J.; Verhaak, R.G.; Aldape, K.D.; Yung, W.K.; Salama, S.R.; Cooper, L.A.; Rheinbay, E.; Miller, C.R.; Vitucci, M.; Morozova, O.; et al. Comprehensive, integrative genomic analysis of diffuse lower-grade gliomas. N. Engl. J. Med. 2015, 372, 2481-2498. [PubMed]
100. Eckel-Passow, J.E.; Lachance, D.H.; Molinaro, A.M.; Walsh, K.M.; Decker, P.A.; Sicotte, H.; Pekmezci, M.; Rice, T.; Kosel, M.L.; Smirnov, I.V.; et al. Glioma groups based on 1p/19q, IDH, and TERT promoter mutations in tumors. N. Engl. J. Med. 2015, 372, 2499-2508.
101. Mwapagha, L.M.; Tiffin, N.; Parker, M.I. Delineation of the HPV11e6 and HPV18e6 pathways in initiating cellular transformation. Front. Oncol. 2017, 7, 258.
102. Vogelsang, M.; Wang, Y.; Veber, N.; Mwapagha, L.M.; Parker, M.I. The cumulative effects of polymorphisms in the DNA mismatch repair genes and tobacco smoking in oesophageal cancer risk. PLoS ONE 2012, 7, e36962.
103. Fishilevich, S.; Nudel, R.; Rappaport, N.; Hadar, R.; Plaschkes, I.; Iny Stein, T.; Rosen, N.; Kohn, A.; Twik, M.; Safran, M.; et al. Genehancer: Genome-wide integration of enhancers and target genes in genecards. Database 2017, 2017.
104. Guo, X.; Long, J.; Zeng, C.; Michailidou, K.; Ghoussaini, M.; Bolla, M.K.;Wang, Q.; Milne, R.L.; Shu, X.O.; Cai, Q.; et al. Fine-scale mapping of the 4q24 locus identifies two independent loci associated with breast cancer risk. Cancer Epidemiol. Biomark. Prev. 2015, 24, 1680-1691.
105. Ombrello, M.J.; Sikora, K.A.; Kastner, D.L. Genetics, genomics, and their relevance to pathology and therapy. Best Pract. Res. Clin. Rheumatol. 2014, 28, 175-189.
106. Simmonds, P.; Loomis, E.; Curry, E. DNA methylation-based chromatin compartments and CHIP-seq profiles reveal transcriptional drivers of prostate carcinogenesis. Genome Med. 2017, 9, 54.
107. Yang, T.Y.; Hsu, L.I.; Chiu, A.W.; Pu, Y.S.; Wang, S.H.; Liao, Y.T.; Wu, M.M.; Wang, Y.H.; Chang, C.H.; Lee, T.C.; et al. Comparison of genome-wide DNA methylation in urothelial carcinomas of patients with and without arsenic exposure. Environ. Res. 2014, 128, 57-63.
108. Mehta, G.; Jalan, R.; Mookerjee, R.P. Cracking the encode: From transcription to therapeutics. Hepatology 2013, 57, 2532-2535.
109. Tragante, V.; Moore, J.H.; Asselbergs, F.W. The encode project and perspectives on pathways. Genet. Epidemiol. 2014, 38, 275-280.
110. Bumpus, S.B.; Evans, B.S.; Thomas, P.M.; Ntai, I.; Kelleher, N.L. A proteomics approach to discovery of natural products and their biosynthetic pathways. Nat. Biotechnol. 2009, 27, 951-956.
111. Martínez-Esteso, M.J.; Martínez-Márquez, A.; Sellés-Marchart, S.; Morante-Carriel, J.A.; Bru-Martínez, R. The role of proteomics in progressing insights into plant secondary metabolism. Front. Plant Sci. 2015, 6, 504.
112. Lum, J.H.; Fung, K.L.; Cheung, P.Y.; Wong, M.S.; Lee, C.H.; Kwok, F.S.; Leung, M.C.; Hui, P.K.; Lo, S.C. Proteome of oriental ginseng Panax ginseng C.A. Meyer and the potential to use it as an identification tool. Proteomics 2002, 2, 1123-1130.
113. Kim, S.W.; Lee, S.H.; Min, C.W.; Jo, I.H.; Bang, K.H.; Hyun, D.-Y.; Agrawal, G.K.; Rakwal, R.; Zargar, S.M.; Gupta, R.; et al. Ginseng (Panax sp.) proteomics: An update. Appl. Biol. Chem. 2017, 60, 311-320.
114. Li, Z.H.; Alex, D.; Siu, S.O.; Chu, I.K.; Renn, J.; Winkler, C.; Lou, S.; Tsui, S.K.; Zhao, H.Y.; Yan, W.R.; et al. Combined in vivo imaging and omics approaches reveal metabolism of icaritin and its glycosides in zebrafish larvae. Mol. BioSyst. 2011, 7, 2128-2138.
115. Hung, M.W.; Zhang, Z.J.; Li, S.; Lei, B.; Yuan, S.; Cui, G.Z.; Man Hoi, P.; Chan, K.; Lee, S.M.Y. From omics to drug metabolism and high content screen of natural product in zebrafish: A new model for discovery of neuroactive compound. Evid.-Based Complement. Altern. Med. 2012, 2012, 605303.
116. Lao, Y.; Wang, X.; Xu, N.; Zhang, H.; Xu, H. Application of proteomics to determine the mechanism of action of traditional Chinese medicine remedies. J. Ethnopharmacol. 2014, 155, 1-8.
117. Guan, D.; Chen, Z. Challenges and recent advances in affinity purification of tag-free proteins. Biotechnol. Lett. 2014, 36, 1391-1406.
118. Novick, D.; Rubinstein, M. Ligand affinity chromatography, an indispensable method for the purification of soluble cytokine receptors and binding proteins. Methods Mol. Biol. 2012, 820, 195-214. [PubMed]
119. Pfaunmiller, E.L.; Paulemond, M.L.; Dupper, C.M.; Hage, D.S. Affinity monolith chromatography: A review of principles and recent analytical applications. Anal. Bioanal. Chem. 2013, 405, 2133-2145.
120. Rix, U.; Gridling, M.; Superti-Furga, G. Compound immobilization and drug-affinity chromatography. Methods Mol. Biol. 2012, 803, 25-38. [PubMed]
121. Wang, H.Z.; Chu, Z.Z.; Chen, C.C.; Cao, A.C.; Tong, X.; Ouyang, C.B.; Yuan, Q.H.;Wang, M.N.;Wu, Z.K.; Wang, H.H.; et al. Recombinant passenger proteins can be conveniently purified by one-step affinity chromatography. PLoS ONE 2015, 10, e0143598.
122. Zhang, X.; Wang, T.; Zhang, H.; Han, B.; Wang, L.; Kang, J. Profiling of drug binding proteins by monolithic affinity chromatography in combination with liquid chromatography-tandem mass spectrometry. J. Chromatogr. A 2014, 1359, 84-90.
123. Schenone, M.; Dancik, V.; Wagner, B.K.; Clemons, P.A. Target identification and mechanism of action in chemical biology and drug discovery. Nat. Chem. Biol. 2013, 9, 232-240.
124. McFedries, A.; Schwaid, A.; Saghatelian, A. Methods for the elucidation of protein-small molecule interactions. Chem. Biol. 2013, 20, 667-673.
125. Rix, U.; Superti-Furga, G. Target profiling of small molecules by chemical proteomics. Nat. Chem. Biol. 2009, 5, 616-624.
126. Lee, H.; Lee, J.W. Target identification for biologically active small molecules using chemical biology approaches. Arch. Pharm. Res. 2016, 39, 1193-1201.
127. Franken, H.; Mathieson, T.; Childs, D.; Sweetman, G.M.;Werner, T.; Togel, I.; Doce, C.; Gade, S.; Bantscheff, M.; Drewes, G.; et al. Thermal proteome profiling for unbiased identification of direct and indirect drug targets using multiplexed quantitative mass spectrometry. Nat. Protoc. 2015, 10, 1567-1593.
128. Jafari, R.; Almqvist, H.; Axelsson, H.; Ignatushchenko, M.; Lundback, T.; Nordlund, P.; Martinez Molina, D. The cellular thermal shift assay for evaluating drug target interactions in cells. Nat. Protoc. 2014, 9, 2100-2122.
129. Lomenick, B.; Hao, R.; Jonai, N.; Chin, R.M.; Aghajan, M.; Warburton, S.; Wang, J.; Wu, R.P.; Gomez, F.; Loo, J.A.; et al. Target identification using drug affinity responsive target stability (darts). Proc. Natl. Acad. Sci. USA 2009, 106, 21984-21989.
130. Schirle, M.; Bantscheff, M.; Kuster, B. Mass spectrometry-based proteomics in preclinical drug discovery. Chem. Biol. 2012, 19, 72-84.
131. Lomenick, B.; Olsen, R.W.; Huang, J. Identification of direct protein targets of small molecules. ACS Chem. Biol. 2011, 6, 34-46.
132. Dejonghe, W.; Russinova, E. Target identification strategies in plant chemical biology. Front. Plant Sci. 2014, 5, 352.
133. West, G.M.; Tucker, C.L.; Xu, T.; Park, S.K.; Han, X.; Yates, J.R., 3rd; Fitzgerald, M.C. Quantitative proteomics approach for identifying protein-drug interactions in complex mixtures using protein stability measurements. Proc. Natl. Acad. Sci. USA 2010, 107, 9078-9082.
134. West, G.M.; Tang, L.; Fitzgerald, M.C. Thermodynamic analysis of protein stability and ligand binding using a chemical modification-and mass spectrometry-based strategy. Anal. Chem. 2008, 80, 4175-4185.
135. Jin, L.;Wang, D.; Gooden, D.M.; Ball, C.H.; Fitzgerald, M.C. Targeted mass spectrometry-based approach for protein-ligand binding analyses in complex biological mixtures using a phenacyl bromide modification strategy. Anal. Chem. 2016, 88, 10987-10993.
136. Saxena, C. Identification of protein binding partners of small molecules using label-free methods. Expert Opin. Drug Discov. 2016, 11, 1017-1025.
137. Strickland, E.C.; Geer, M.A.; Hong, J.; Fitzgerald, M.C. False-positive rate determination of protein target discovery using a covalent modification-and mass spectrometry-based proteomics platform. J. Am. Soc. Mass Spectrom. 2014, 25, 132-140.
138. Dearmond, P.D.; Xu, Y.; Strickland, E.C.; Daniels, K.G.; Fitzgerald, M.C. Thermodynamic analysis of protein-ligand interactions in complex biological mixtures using a shotgun proteomics approach. J. Proteome Res. 2011, 10, 4948-4958.
139. Tran, D.T.; Adhikari, J.; Fitzgerald, M.C. Stableisotope labeling with amino acids in cell culture (SILAC)-based strategy for proteome-wide thermodynamic analysis of protein-ligand binding interactions. Mol. Cell. Proteom. 2014, 13, 1800-1813.
140. Geiger, T.; Wisniewski, J.R.; Cox, J.; Zanivan, S.; Kruger, M.; Ishihama, Y.; Mann, M. Use of stable isotope labeling by amino acids in cell culture as a spike-in standard in quantitative proteomics. Nat. Protoc. 2011, 6, 147-157.
141. Hoedt, E.; Zhang, G.; Neubert, T.A. Stable isotope labeling by amino acids in cell culture (SILAC) for quantitative proteomics. Adv. Exp. Med. Biol. 2014, 806, 93-106. [PubMed]
142. Larance, M.; Bailly, A.P.; Pourkarimi, E.; Hay, R.T.; Buchanan, G.; Coulthurst, S.; Xirodimas, D.P.; Gartner, A.; Lamond, A.I. Stable-isotope labeling with amino acids in nematodes. Nat. Methods 2011, 8, 849-851.
143. Ong, S.E.; Mann, M. A practical recipe for stable isotope labeling by amino acids in cell culture (SILAC). Nat. Protoc. 2006, 1, 2650-2660.
144. Zhang, L.; Jin, J.; Zhang, L.; Hu, R.; Gao, L.; Huo, X.; Liu, D.; Ma, X.;Wang, C.; Han, J.; et al. Quantitative analysis of differential protein expression in cervical carcinoma cells after zeylenone treatment by stable isotope labeling with amino acids in cell culture. J. Proteom. 2015, 126, 279-287.
145. Martinez Molina, D.; Jafari, R.; Ignatushchenko, M.; Seki, T.; Larsson, E.A.; Dan, C.; Sreekumar, L.; Cao, Y.; Nordlund, P. Monitoring drug target engagement in cells and tissues using the cellular thermal shift assay. Science 2013, 341, 84-87.
146. Schirle, M.; Jenkins, J.L. Identifying compound efficacy targets in phenotypic drug discovery. Drug Discov. Today 2016, 21, 82-89.
147. Tang, H.; Duggan, S.; Richardson, P.L.; Marin, V.; Warder, S.E.; McLoughlin, S.M. Target identification of compounds from a cell viability phenotypic screen using a bead/lysate-based affinity capture platform. J. Biomol. Screen. 2016, 21, 201-211.
148. Huber, K.V.; Olek, K.M.; Muller, A.C.; Tan, C.S.; Bennett, K.L.; Colinge, J.; Superti-Furga, G. Proteome-wide drug and metabolite interaction mapping by thermal-stability profiling. Nat. Methods 2015, 12, 1055-1057.
149. Reinhard, F.B.; Eberhard, D.; Werner, T.; Franken, H.; Childs, D.; Doce, C.; Savitski, M.F.; Huber, W.; Bantscheff, M.; Savitski, M.M.; et al. Thermal proteome profiling monitors ligand interactions with cellular membrane proteins. Nat. Methods 2015, 12, 1129-1131.
150. Savitski, M.M.; Reinhard, F.B.; Franken, H.; Werner, T.; Savitski, M.F.; Eberhard, D.; Martinez Molina, D.; Jafari, R.; Dovega, R.B.; Klaeger, S.; et al. Tracking cancer drugs in living cells by thermal profiling of the proteome. Science 2014, 346, 1255784.
151. Becher, I.; Werner, T.; Doce, C.; Zaal, E.A.; Togel, I.; Khan, C.A.; Rueger, A.; Muelbaier, M.; Salzer, E.; Berkers, C.R.; et al. Thermal profiling reveals phenylalanine hydroxylase as an off-target of panobinostat. Nat. Chem. Biol. 2016, 12, 908-910.
152. Mateus, A.; Maatta, T.A.; Savitski, M.M. Thermal proteome profiling: Unbiased assessment of protein state through heat-induced stability changes. Proteome Sci. 2016, 15, 13.
153. Ho, C.H.; Magtanong, L.; Barker, S.L.; Gresham, D.; Nishimura, S.; Natarajan, P.; Koh, J.L.Y.; Porter, J.; Gray, C.A.; Andersen, R.J.; et al. A molecular barcoded yeast ORF library enables mode-of-action analysis of bioactive compounds. Nat. Biotechnol. 2009, 27, 369-377.
154. Jung, H.J.; Kwon, H.J. Target deconvolution of bioactive small molecules: The heart of chemical biology and drug discovery. Arch. Pharm. Res. 2015, 38, 1627-1641.
155. Bassik, M.C.; Kampmann, M.; Lebbink, R.J.;Wang, S.; Hein, M.Y.; Poser, I.;Weibezahn, J.; Horlbeck, M.A.; Chen, S.; Mann, M.; et al. A systematic mammalian genetic interaction map reveals pathways underlying ricin susceptibility. Cell 2013, 152, 909-922.
156. Shalem, O.; Sanjana, N.E.; Hartenian, E.; Shi, X.; Scott, D.A.; Mikkelson, T.; Heckl, D.; Ebert, B.L.; Root, D.E.; Doench, J.G.; et al. Genome-scale crispr-cas9 knockout screening in human cells. Science 2014, 343, 84-87.
157. Kasap, C.; Elemento, O.; Kapoor, T.M. Drugtargetseqr: A genomics-and CRISPR-Cas9-based method to analyze drug targets. Nat. Chem. Biol. 2014, 10, 626-628.
158. Ipsaro, J.J.; Shen, C.; Arai, E.; Xu, Y.; Kinney, J.B.; Joshua-Tor, L.; Vakoc, C.R.; Shi, J. Rapid generation of drug-resistance alleles at endogenous loci using CRISPR-Cas9 indel mutagenesis. PLoS ONE 2017, 12, e0172177.
159. Neggers, J.E.; Vercruysse, T.; Jacquemyn, M.; Vanstreels, E.; Baloglu, E.; Shacham, S.; Crochiere, M.; Landesman, Y.; Daelemans, D. Identifying drug-target selectivity of small-molecule CRM1/XPO1 inhibitors by CRISPR/Cas9 genome editing. Chem. Biol. 2015, 22, 107-116.
160. Liu, X.; Locasale, J.W. Metabolomics: A primer. Trends Biochem. Sci. 2017, 42, 274-284.
161. Clish, C.B. Metabolomics: An emerging but powerful tool for precision medicine. Cold Spring Harb. Mol. Case Stud. 2015, 1, a000588.
162. Nicholson, J.K.; Lindon, J.C. Systems biology: Metabonomics. Nature 2008, 455, 7216.
163. Perez-Pinera, P.; Ousterout, D.G.; Gersbach, C.A. Advances in targeted genome editing. Curr. Opin. Chem. Biol. 2012, 16, 268-277.
164. Siminovitch, L. Genetic manipulation: Now is the time to consider controls. Sci. Forum 1973, 6, 7-11.
165. Yarmush, M.L.; Banta, S. Metabolic engineering: Advances in modeling and intervention in health and disease. Ann. Rev. Biomed. Eng. 2003, 5, 349-381.
166. Yan, T.; Fu, Q.;Wang, J.; Ma, S. UPLC-MS/MS determination of ephedrine, methylephedrine, amygdalin and glycyrrhizic acid in beagle plasma and its application to a pharmacokinetic study after oral administration of Ma Huang Tang. Drug. Test. Anal. 2015, 7, 158-163.
167. Ekow Thomford, N.; Dzobo, K.; Adu, F.; Chirikure, S.;Wonkam, A.; Dandara, C. Bush mint (Hyptis suaveolens) and spreading hogweed (Boerhavia diffusa) medicinal plant extracts differentially affect activities of CYP1A2, CYP2D6 and CYP3A4 enzymes. J. Ethnopharmacol. 2018, 211, 58-69.
168. Xie, G.; Plumb, R.; Su, M.; Xu, Z.; Zhao, A.; Qiu, M.; Long, X.; Liu, Z.; Jia,W. Ultra-performance LC/TOF MS analysis of medicinal Panax herbs for metabolomic research. J. Sep. Sci. 2008, 31, 1015-1026.
169. Park, H.-W.; In, G.; Kim, J.-H.; Cho, B.-G.; Han, G.-H.; Chang, I.-M. Metabolomic approach for discrimination of processed ginseng genus (Panax ginseng and Panax quinquefolius) using UPLC-QTOF MS. J. Ginseng Res. 2014, 38, 59-65.
170. Korotcov, A.; Tkachenko, V.; Russo, D.P.; Ekins, S. Comparison of deep learning with multiple machine learning methods and metrics using diverse drug discovery data sets. Mol. Pharm. 2017, 14, 4462-4475.
171. Oprea, T.I.; Matter, H. Integrating virtual screening in lead discovery. Curr. Opin. Chem. Biol. 2004, 8, 349-358.
172. Beck, A.; Eberherr, C.; Hagemann, M.; Cairo, S.; Haberle, B.; Vokuhl, C.; von Schweinitz, D.; Kappler, R. Connectivity map identifies HDAC inhibition as a treatment option of high-risk hepatoblastoma. Cancer Biol. Ther. 2016, 17, 1168-1176.
173. Brum, A.M.; van de Peppel, J.; van der Leije, C.S.; Schreuders-Koedam, M.; Eijken, M.; van der Eerden, B.C.; van Leeuwen, J.P. Connectivity map-based discovery of parbendazole reveals targetable human osteogenic pathway. Proc. Natl. Acad. Sci. USA 2015, 112, 12711-12716.
174. Cheng, J.; Yang, L.; Kumar, V.; Agarwal, P. Systematic evaluation of connectivity map for disease indications. Genome Med. 2014, 6, 95.
175. Lamb, J. The connectivity map: A new tool for biomedical research. Nat. Rev. Cancer 2007, 7, 54-60.
176. Lamb, J.; Crawford, E.D.; Peck, D.; Modell, J.W.; Blat, I.C.; Wrobel, M.J.; Lerner, J.; Brunet, J.P.; Subramanian, A.; Ross, K.N.; et al. The connectivity map: Using gene-expression signatures to connect small molecules, genes, and disease. Science 2006, 313, 1929-1935.
177. Hahn, C.K.; Berchuck, J.E.; Ross, K.N.; Kakoza, R.M.; Clauser, K.; Schinzel, A.C.; Ross, L.; Galinsky, I.; Davis, T.N.; Silver, S.J.; et al. Proteomic and genetic approaches identify Syk as an AML target. Cancer Cell 2009, 16, 281-294.
178. Nair, M.; Sandhu, S.S.; Sharma, A.K. Prognostic and predictive biomarkers in cancer. Curr. Cancer Drug Targets 2014, 14, 477-504.
179. Narayanan, R. Druggable cancer secretome: Neoplasm-associated traits. Cancer Genom. Proteom. 2015, 12, 119-131.
180. Roti, G.; Stegmaier, K. Genetic and proteomic approaches to identify cancer drug targets. Br. J. Cancer 2012, 106, 254-261.
181. Verma, M.; Wright, G.L., Jr.; Hanash, S.M.; Gopal-Srivastava, R.; Srivastava, S. Proteomic approaches within the NCI early detection research network for the discovery and identification of cancer biomarkers. Ann. N. Y. Acad. Sci. 2001, 945, 103-115.
182. Awale, M.; Visini, R.; Probst, D.; Arus-Pous, J.; Reymond, J.L. Chemical space: Big data challenge for molecular diversity. Chimia 2017, 71, 661-666.
183. Denny, J.C.; Van Driest, S.L.;Wei,W.Q.; Roden, D.M. The influence of big (clinical) data and genomics on precision medicine and drug development. Clin. Pharmacol. Ther. 2018, 103, 409-418.
184. Singh, G.; Schulthess, D.; Hughes, N.; Vannieuwenhuyse, B.; Kalra, D. Real world big data for clinical research and drug development. Drug Discov. Today 2018, 23, 650-660.
185. Bento, A.P.; Gaulton, A.; Hersey, A.; Bellis, L.J.; Chambers, J.; Davies, M.; Kruger, F.A.; Light, Y.; Mak, L.; McGlinchey, S.; et al. The ChEMBL bioactivity database: An update. Nucleic Acids Res. 2014, 42, D1083-D1090.
186. Gaulton, A.; Bellis, L.J.; Bento, A.P.; Chambers, J.; Davies, M.; Hersey, A.; Light, Y.; McGlinchey, S.; Michalovich, D.; Al-Lazikani, B.; et al. Chembl: A large-scale bioactivity database for drug discovery. Nucleic Acids Res. 2012, 40, D1100-D1107.
187. Gaulton, A.; Hersey, A.; Nowotka, M.; Bento, A.P.; Chambers, J.; Mendez, D.; Mutowo, P.; Atkinson, F.; Bellis, L.J.; Cibrian-Uhalte, E.; et al. The ChEMBL database in 2017. Nucleic Acids Res. 2017, 45, D945-D954.
188. Kruger, F.A.; Rostom, R.; Overington, J.P. Mapping small molecule binding data to structural domains. BMC Bioinform. 2012, 13, S11.
189. Roos, D.S. Computational biology. Bioinformatics-Trying to swim in a sea of data. Science 2001, 291, 1260-1261.
190. Jennings, A.; Tennant, M. Discovery strategies in a pharmaceutical setting: The application of computational techniques. Expert Opin. Drug Discov. 2006, 1, 709-721.
191. Chen, Y.P.; Chen, F. Identifying targets for drug discovery using bioinformatics. Expert Opin. Ther. Targets 2008, 12, 383-389.
192. Segal, M.R.; Xiong, H.; Bengtsson, H.; Bourgon, R.; Gentleman, R. Querying genomic databases: Refining the connectivity map. Stat. Appl. Genet. Mol. Biol. 2012, 11.
193. Kim, R.S.; Goossens, N.; Hoshida, Y. Use of big data in drug development for precision medicine. Expert Rev. Precis. Med. Drug Dev. 2016, 1, 245-253.
194. Cappon, G.D. Nonclinical support of pediatric drug development in a global context: An industry perspective. Birth Defects Res. Part B Dev. Reprod. Toxicol. 2011, 92, 269-272.
195. Kaneko, T.; Cooper, C.; Mdluli, K. Challenges and opportunities in developing novel drugs for TB. Future Med. Chem. 2011, 3, 1373-1400.
196. Morford, L.L.; Bowman, C.J.; Blanset, D.L.; Bogh, I.B.; Chellman, G.J.; Halpern, W.G.; Weinbauer, G.F.; Coogan, T.P. Preclinical safety evaluations supporting pediatric drug development with biopharmaceuticals:Strategy, challenges, current practices. Birth Defects Res. Part B Dev. Reprod. Toxicol. 2011, 92, 359-380.
197. Beggs, N.F.; Dobrovolny, H.M. Determining drug efficacy parameters for mathematical models of influenza. J. Biol. Dyn. 2015, 9, 332-346.
198. Hwang,W.; Choi, J.; Kwon, M.; Lee, D. Context-specific functional module based drug efficacy prediction. BMC Bioinform. 2016, 17 (Suppl. 6).
199. Jimenez-Diaz, M.B.; Viera, S.; Fernandez-Alvaro, E.; Angulo-Barturen, I. Animal models of efficacy to accelerate drug discovery in malaria. Parasitology 2014, 141, 93-103.
200. Nelson, M.R.; Johnson, T.;Warren, L.; Hughes, A.R.; Chissoe, S.L.; Xu, C.F.;Waterworth, D.M. The genetics of drug efficacy: Opportunities and challenges. Nat. Rev. Genet. 2016, 17, 197-206.
201. Tsugawa, J.; Onozawa, R.; Fukae, J.; Mishima, T.; Fujioka, S.; Tsuboi, Y. Impact of insufficient drug efficacy of antiparkinson agents on patient’s quality of life: A cross-sectional study. BMC Neurol. 2015, 15, 105.
202. Gange, S.J.; Golub, E.T. From smallpox to big data: The next 100 years of epidemiologic methods. Am. J. Epidemiol. 2016, 183, 423-426.
203. Docherty, A.B.; Lone, N.I. Exploiting big data for critical care research. Curr. Opin. Crit. Care 2015, 21, 467-472.
204. Greene, C.S.; Tan, J.; Ung, M.; Moore, J.H.; Cheng, C. Big data bioinformatics. J. Cell. Physiol. 2014, 229, 1896-1900.
205. Tan, S.S.; Gao, G.; Koch, S. Big data and analytics in healthcare. Methods Inf. Med. 2015, 54, 546-547.
206. Wasser, T.; Haynes, K.; Barron, J.; Cziraky, M. Using ‘big data’ to validate claims made in the pharmaceutical approval process. J. Med. Econ. 2015, 18, 1013-1019.
207. Reshef, D.N.; Reshef, Y.A.; Finucane, H.K.; Grossman, S.R.; McVean, G.; Turnbaugh, P.J.; Lander, E.S.; Mitzenmacher, M.; Sabeti, P.C. Detecting novel associations in large data sets. Science 2011, 334, 1518-1524.
208. Omberg, L.; Ellrott, K.; Yuan, Y.; Kandoth, C.; Wong, C.; Kellen, M.R.; Friend, S.H.; Stuart, J.; Liang, H.; Margolin, A.A. Enabling transparent and collaborative computational analysis of 12 tumor types within the cancer genome atlas. Nat. Genet. 2013, 45, 1121-1126.
209. Chen, R.; Mias, G.I.; Li-Pook-Than, J.; Jiang, L.; Lam, H.Y.; Chen, R.; Miriami, E.; Karczewski, K.J.; Hariharan, M.; Dewey, F.E.; et al. Personal omics profiling reveals dynamic molecular and medical phenotypes. Cell 2012, 148, 1293-1307.
210. Chapman, T. Lab automation and robotics: Automation on the move. Nature 2003, 421, 661-666.
211. King, R.D.; Rowland, J.; Oliver, S.G.; Young, M.; Aubrey, W.; Byrne, E.; Liakata, M.; Markham, M.; Pir, P.; Soldatova, L.N.; et al. The automation of science. Science 2009, 324, 85-89.
212. Sparkes, A.; Aubrey, W.; Byrne, E.; Clare, A.; Khan, M.N.; Liakata, M.; Markham, M.; Rowland, J.; Soldatova, L.N.; Whelan, K.E.; et al. Towards robot scientists for autonomous scientific discovery. Autom. Exp. 2010, 2, 1.
213. Meanwell, N.A. Improving drug design: An update on recent applications of efficiency metrics, strategies for replacing problematic elements, and compounds in non-traditional drug space. Chem. Res. Toxicol. 2016, 29, 564-616.
214. MacConnell, A.B.; Price, A.K.; Paegel, B.M. An integrated microfluidic processor for DNA-encoded combinatorial library functional screening. ACS Comb. Sci. 2017, 19, 181-192.
215. Baranczak, A.; Tu, N.P.; Marjanovic, J.; Searle, P.A.; Vasudevan, A.; Djuric, S.W. Integrated platform for expedited synthesis-purification-testing of small molecule libraries. ACS Med. Chem. Lett. 2017, 8, 461-465.
216. Gupta, A.; Muller, A.T.; Huisman, B.J.H.; Fuchs, J.A.; Schneider, P.; Schneider, G. Generative recurrent networks for de novo drug design. Mol. Inform. 2017.
217. Merk, D.; Friedrich, L.; Grisoni, F.; Schneider, G. De novo design of bioactive small molecules by artificial intelligence. Mol. Inform. 2018.
218. Zhang, L.; Tan, J.; Han, D.; Zhu, H. From machine learning to deep learning: Progress in machine intelligence for rational drug discovery. Drug Discov. Today 2017, 22, 1680-1685.
219. Duch, W.; Swaminathan, K.; Meller, J. Artificial intelligence approaches for rational drug design and discovery. Curr. Pharm. Des. 2007, 13, 1497-1508.
220. Esch, E.W.; Bahinski, A.; Huh, D. Organs-on-chips at the frontiers of drug discovery. Nat. Rev. Drug Discov. 2015, 14, 248-260.
221. Eglen, R.M.; Randle, D.H. Drug discovery goes three-dimensional: Goodbye to flat high-throughput screening? Assay Drug Dev. Technol. 2015, 13, 262-265.
222. Ozdemir, V.; Patrinos, G.P. David bowie and the art of slow innovation: A fast-second winner strategy for biotechnology and precision medicine global development. Omics 2017, 21, 633-637.
223. Burke, M.D.; Lalic, G. Teaching target-oriented and diversity-oriented organic synthesis at Harvard University. Chem. Biol. 2002, 9, 535-541.
224. Schreiber, S.L. Target-oriented and diversity-oriented organic synthesis in drug discovery. Science 2000, 287, 1964-1969.
225. Maier, M.E. Design and synthesis of analogues of natural products. Org. Biomol. Chem. 2015, 13, 5302-5343.
226. Basu, S.; Ellinger, B.; Rizzo, S.; Deraeve, C.; Schurmann, M.; Preut, H.; Arndt, H.D.; Waldmann, H. Biology-oriented synthesis of a natural-product inspired oxepane collection yields a small-molecule activator of the Wnt-pathway. Proc. Natl. Acad. Sci. USA 2011, 108, 6805-6810.
227. Kaiser, M.; Wetzel, S.; Kumar, K.; Waldmann, H. Biology-inspired synthesis of compound libraries. Cell. Mol. Life Sci. 2008, 65, 1186-1201.
228. Wetzel, S.; Bon, R.S.; Kumar, K.; Waldmann, H. Biology-oriented synthesis. Angew. Chem. Int. Ed. Engl. 2011, 50, 10800-10826.
229. Wender, P.A.; Quiroz, R.V.; Stevens, M.C. Function through synthesis-informed design. Acc. Chem. Res. 2015, 48, 752-760.
230. Wender, P.A.; Verma, V.A.; Paxton, T.J.; Pillow, T.H. Function-oriented synthesis, step economy, and drug design. Acc. Chem. Res. 2008, 41, 40-49.
231. Zhu, Q.; Sun, Y.; Challa, S.; Ding, Y.; Lajiness, M.S.; Wild, D.J. Semantic inference using chemogenomics data for drug discovery. BMC Bioinform. 2011, 12, 256.
232. White, D.; Wilson, R.C. Generative models for chemical structures. J. Chem. Inf. Model. 2010, 50, 1257-1274.
233. Rubio, D.M.; Schoenbaum, E.E.; Lee, L.S.; Schteingart, D.E.; Marantz, P.R.; Anderson, K.E.; Platt, L.D.; Baez, A.; Esposito, K. Defining translational research: Implications for training. Acad. Med. 2010, 85, 470-475.
234. Jing, Y.; Bian, Y.; Hu, Z.;Wang, L.; Xie, X.S. Deep learning for drug design: An artificial intelligence paradigm for drug discovery in the big data era. AAPS J. 2018, 20, 58.
235. Reutlinger, M.; Rodrigues, T.; Schneider, P.; Schneider, G. Combining on-chip synthesis of a focused combinatorial library with computational target prediction reveals imidazopyridine GPCR ligands. Angew. Chem. Int. Ed. Engl. 2014, 53, 582-585.
236. Schneider, G. Automating drug discovery. Nat. Rev. Drug Discov. 2018, 17, 97-113.
237. Reutlinger, M.; Rodrigues, T.; Schneider, P.; Schneider, G. Multi-objective molecular de novo design by adaptive fragment prioritization. Angew. Chem. Int. Ed. Engl. 2014, 53, 4244-4248.
238. Schneider, P.; Rothlisberger, M.; Reker, D.; Schneider, G. Spotting and designing promiscuous ligands for drug discovery. Chem. Commun. 2016, 52, 1135-1138.
239. Wang, L.; Wu, Y.; Deng, Y.; Kim, B.; Pierce, L.; Krilov, G.; Lupyan, D.; Robinson, S.; Dahlgren, M.K.; Greenwood, J.; et al. Accurate and reliable prediction of relative ligand binding potency in prospective drug discovery by way of a modern free-energy calculation protocol and force field. J. Am. Chem. Soc. 2015, 137, 2695-2703.
240. Besnard, J.; Ruda, G.F.; Setola, V.; Abecassis, K.; Rodriguiz, R.M.; Huang, X.P.; Norval, S.; Sassano, M.F.; Shin, A.I.;Webster, L.A.; et al. Automated design of ligands to polypharmacological profiles. Nature 2012, 492, 215-220.
241. Koppitz, M.; Eis, K. Automated medicinal chemistry. Drug Discov. Today 2006, 11, 561-568.
242. Sutherland, J.D.; Tu, N.P.; Nemcek, T.A.; Searle, P.A.; Hochlowski, J.E.; Djuric, S.W.; Pan, J.Y. An automated synthesis-purification-sample-management platform for the accelerated generation of pharmaceutical candidates. J. Lab. Autom. 2014, 19, 176-182.
243. Godfrey, A.G.; Masquelin, T.; Hemmerle, H. A remote-controlled adaptive medchem lab: An innovative approach to enable drug discovery in the 21st century. Drug Discov. Today 2013, 18, 795-802.
244. Nicolaou, C.A.; Watson, I.A.; Hu, H.; Wang, J. The proximal lilly collection: Mapping, exploring and exploiting feasible chemical space. J. Chem. Inf. Model. 2016, 56, 1253-1266.
245. Li, J.; Ballmer, S.G.; Gillis, E.P.; Fujii, S.; Schmidt, M.J.; Palazzolo, A.M.; Lehmann, J.W.; Morehouse, G.F.; Burke, M.D. Synthesis of many different types of organic small molecules using one automated process. Science 2015, 347, 1221-1226.
246. Stalder, R.; Roth, G.P. Preparative microfluidic electrosynthesis of drug metabolites. ACS Med. Chem. Lett. 2013, 4, 1119-1123.
247. Genovino, J.; Sames, D.; Hamann, L.G.; Toure, B.B. Accessing drug metabolites via transition-metal catalyzed c-h oxidation: The liver as synthetic inspiration. Angew. Chem. Int. Ed. Engl. 2016, 55, 14218-14238.
248. LaPorte, T.L.; Wang, C. Continuous processes for the production of pharmaceutical intermediates and active pharmaceutical ingredients. Curr. Opin. Drug Discov. Dev. 2007, 10, 738-745.
249. Chin, P.; Barney, W.S.; Pindzola, B.A. Microstructured reactors as tools for the intensification of pharmaceutical reactions and processes. Curr. Opin. Drug Discov. Dev. 2009, 12, 848-861.
250. Saaby, S.; Knudsen, K.R.; Ladlow, M.; Ley, S.V. The use of a continuous flow-reactor employing a mixed hydrogen-liquid flow stream for the efficient reduction of imines to amines. Chem. Commun. 2005, 2909-2911.
251. Brzozowski, M.; O’Brien, M.; Ley, S.V.; Polyzos, A. Flow chemistry: Intelligent processing of gas-liquid transformations using a tube-in-tube reactor. Acc. Chem. Res. 2015, 48, 349-362.
252. Loskill, P.; Sezhian, T.; Tharp, K.M.; Lee-Montiel, F.T.; Jeeawoody, S.; Reese, W.M.; Zushin, P.H.; Stahl, A.; Healy, K.E. Wat-on-a-chip: A physiologically relevant microfluidic system incorporating white adipose tissue. Lab Chip 2017, 17, 1645-1654.
253. Eyer, K.; Stratz, S.; Kuhn, P.; Kuster, S.K.; Dittrich, P.S. Implementing enzyme-linked immunosorbent assays on a microfluidic chip to quantify intracellular molecules in single cells. Anal. Chem. 2013, 85, 3280-3287.
254. Ferrari, M. Frontiers in cancer nanomedicine: Directing mass transport through biological barriers. Trends Biotechnol. 2010, 28, 181-188.
255. Zhang, Y.S.; Zhang, Y.N.; Zhang, W. Cancer-on-a-chip systems at the frontier of nanomedicine. Drug Discov. Today 2017, 22, 1392-1399.
256. Galler, K.; Brautigam, K.; Grosse, C.; Popp, J.; Neugebauer, U. Making a big thing of a small cell-recent advances in single cell analysis. Analyst 2014, 139, 1237-1273.
257. Kayala, M.A.; Azencott, C.A.; Chen, J.H.; Baldi, P. Learning to predict chemical reactions. J. Chem. Inf. Model. 2011, 51, 2209-2222.
258. Reynolds, C.R.; Muggleton, S.H.; Sternberg, M.J. Incorporating virtual reactions into a logic-based ligand-based virtual screening method to discover new leads. Mol. Inform. 2015, 34, 615-625.
259. Kowalik, M.; Gothard, C.M.; Drews, A.M.; Gothard, N.A.;Weckiewicz, A.; Fuller, P.E.; Grzybowski, B.A.; Bishop, K.J. Parallel optimization of synthetic pathways within the network of organic chemistry. Angew. Chem. Int. Ed. Engl. 2012, 51, 7928-7932.
260. Szymkuc, S.; Gajewska, E.P.; Klucznik, T.; Molga, K.; Dittwald, P.; Startek, M.; Bajczyk, M.; Grzybowski, B.A. Computer-assisted synthetic planning: The end of the beginning. Angew. Chem. Int. Ed. Engl. 2016, 55, 5904-5937.
261. Baker, M. Europe bets on drug discovery. Nature 2013, 494, 20.
262. Lopez-Rubio, E.; Elizondo, D.A.; Grootveld, M.; Jerez, J.M.; Luque-Baena, R.M. Computational intelligence techniques in medicine. Comput. Math. Methods Med. 2015, 2015, 196976.
263. Montanez-Godinez, N.; Martinez-Olguin, A.C.; Deeb, O.; Garduno-Juarez, R.; Ramirez-Galicia, G. QSAR/QSPR as an application of artificial neural networks. Methods Mol. Biol. 2015, 1260, 319-333.
264. Wesolowski, M.; Suchacz, B. Artificial neural networks: Theoretical background and pharmaceutical applications: A review. J. AOAC Int. 2012, 95, 652-668.
265. Baskin, I.I.; Winkler, D.; Tetko, I.V. A renaissance of neural networks in drug discovery. Expert Opin. Drug Discov. 2016, 11, 785-795.
266. Nikolsky, Y.; Nikolskaya, T.; Bugrim, A. Biological networks and analysis of experimental data in drug discovery. Drug Discov. Today 2005, 10, 653-662.
267. LeCun, Y.; Bengio, Y.; Hinton, G. Deep learning. Nature 2015, 521, 436-444.
268. Lipinski, C.A. Drug-like properties and the causes of poor solubility and poor permeability. J. Pharmacol. Toxicol. Methods 2000, 44, 235-249.
269. Congreve, M.; Carr, R.; Murray, C.; Jhoti, H. A ‘rule of three’ for fragment-based lead discovery? Drug Discov. Today 2003, 8, 876-877.
270. Van Molle, I.; Thomann, A.; Buckley, D.L.; So, E.C.; Lang, S.; Crews, C.M.; Ciulli, A. Dissecting fragment-based lead discovery at the von Hippel-Lindau protein: Hypoxia inducible factor 1alpha protein-protein interface. Chem. Biol. 2012, 19, 1300-1312.
271. Zuegg, J.; Cooper, M.A. Drug-likeness and increased hydrophobicity of commercially available compound libraries for drug screening. Curr. Top. Med. Chem. 2012, 12, 1500-1513.
272. Ntie-Kang, F.; Lifongo, L.L.; Judson, P.N.; Sippl,W.; Efange, S.M. How “drug-like” are naturally occurring anti-cancer compounds? J. Mol. Model. 2014, 20, 2069.
273. Grabowski, K.; Baringhaus, K.H.; Schneider, G. Scaffold diversity of natural products: Inspiration for combinatorial library design. Nat. Prod. Rep. 2008, 25, 892-904.
274. Elumalai, N.; Berg, A.; Natarajan, K.; Scharow, A.; Berg, T. Nanomolar inhibitors of the transcription factor STAT5b with high selectivity over STAT5a. Angew. Chem. Int. Ed. Engl. 2015, 54, 4758-4763.
275. Bon, R.S.; Waldmann, H. Bioactivity-guided navigation of chemical space. Acc. Chem. Res. 2010, 43, 1103-1114.
276. Renner, S.; van Otterlo, W.A.; Dominguez Seoane, M.; Mocklinghoff, S.; Hofmann, B.; Wetzel, S.; Schuffenhauer, A.; Ertl, P.; Oprea, T.I.; Steinhilber, D.; et al. Bioactivity-guided mapping and navigation of chemical space. Nat. Chem. Biol. 2009, 5, 585-592.
277. Wetzel, S.; Klein, K.; Renner, S.; Rauh, D.; Oprea, T.I.; Mutzel, P.;Waldmann, H. Interactive exploration of chemical space with scaffold hunter. Nat. Chem. Biol. 2009, 5, 581-583.
278. Rodrigues, T.; Reker, D.; Schneider, P.; Schneider, G. Counting on natural products for drug design. Nat. Chem. 2016, 8, 531-541.
279. Lagunin, A.; Stepanchikova, A.; Filimonov, D.; Poroikov, V. Pass: Prediction of activity spectra for biologically active substances. Bioinformatics 2000, 16, 747-748.
280. Stepanchikova, A.V.; Lagunin, A.A.; Filimonov, D.A.; Poroikov, V.V. Prediction of biological activity spectra for substances: Evaluation on the diverse sets of drug-like structures. Curr. Med. Chem. 2003, 10, 225-233.
281. Reker, D.; Rodrigues, T.; Schneider, P.; Schneider, G. Identifying the macromolecular targets of de novo-designed chemical entities through self-organizing map consensus. Proc. Natl. Acad. Sci. USA 2014, 111, 4067-4072.
282. Schneider, G.; Reker, D.; Rodrigues, T.; Schneider, P. Coping with polypharmacology by computational medicinal chemistry. Chimia 2014, 68, 648-653.
283. Sliwoski, G.; Kothiwale, S.; Meiler, J.; Lowe, E.W. Computational methods in drug discovery. Pharmacol. Rev. 2014, 66, 334-395.
284. DiMasi, J.A.; Feldman, L.; Seckler, A.; Wilson, A. Trends in risks associated with new drug development:Success rates for investigational drugs. Clin. Pharmacol. Ther. 2010, 87, 272-277.
285. DiMasi, J.A.; Reichert, J.M.; Feldman, L.; Malins, A. Clinical approval success rates for investigational cancer drugs. Clin. Pharmacol. Ther. 2013, 94, 329-335.
286. Hay, M.; Thomas, D.W.; Craighead, J.L.; Economides, C.; Rosenthal, J. Clinical development success rates for investigational drugs. Nat. Biotechnol. 2014, 32, 40-51.
287. Loong, H.H.; Siu, L.L. Selecting the best drugs for phase I clinical development and beyond. In American Society of Clinical Oncology Educational Book. American Society of Clinical Oncology. Meeting; American Society of Clinical Oncology: Alexandria, VA, USA, 2013; pp. 469-473.
288. Chavan, S.; Nicholls, I.A.; Karlsson, B.C.; Rosengren, A.M.; Ballabio, D.; Consonni, V.; Todeschini, R. Towards global qsar model building for acute toxicity: Munro database case study. Int. J. Mol. Sci. 2014, 15, 18162-18174.
289. Cherkasov, A.; Muratov, E.N.; Fourches, D.; Varnek, A.; Baskin, I.I.; Cronin, M.; Dearden, J.; Gramatica, P.; Martin, Y.C.; Todeschini, R.; et al. Qsar modeling: Where have you been? Where are you going to? J. Med. Chem. 2014, 57, 4977-5010.
290. Devillers, J. Methods for building QSARs. Methods Mol. Biol. 2013, 930, 3-27. [PubMed]
291. Sullivan, K.M.; Manuppello, J.R.; Willett, C.E. Building on a solid foundation: SAR and QSAR as a fundamental strategy to reduce animal testing. SAR QSAR Environ. Res. 2014, 25, 357-365.
292. Kirchmair, J.; Goller, A.H.; Lang, D.; Kunze, J.; Testa, B.; Wilson, I.D.; Glen, R.C.; Schneider, G. Predicting drug metabolism: Experiment and/or computation? Nat. Rev. Drug Discov. 2015, 14, 387-404.
293. Mukherjee, G.; Lal Gupta, P.; Jayaram, B. Predicting the binding modes and sites of metabolism of xenobiotics. Mol. BioSyst. 2015, 11, 1914-1924.
294. Xiao, X.; Min, J.L.; Lin, W.Z.; Liu, Z.; Cheng, X.; Chou, K.C. Idrug-target: Predicting the interactions between drug compounds and target proteins in cellular networking via benchmark dataset optimization approach. J. Biomol. Struct. Dyn. 2015, 33, 2221-2233.
295. Zhang, W.; Liu, F.; Luo, L.; Zhang, J. Predicting drug side effects by multi-label learning and ensemble learning. BMC Bioinform. 2015, 16, 365.
296. Bastian, L.; Hof, J.; Pfau, M.; Fichtner, I.; Eckert, C.; Henze, G.; Prada, J.; von Stackelberg, A.; Seeger, K.; Shalapour, S. Synergistic activity of bortezomib and hdaci in preclinical models of b-cell precursor acute lymphoblastic leukemia via modulation of p53, pi3k/akt, and nf-kappab. Clin. Cancer Res. 2013, 19, 1445-1457.
297. Stanciu-Herrera, C.; Morgan, C.; Herrera, L. Anti-cd19 and anti-cd22 monoclonal antibodies increase the effectiveness of chemotherapy in pre-b acute lymphoblastic leukemia cell lines. Leukemia Res. 2008, 32, 625-632.
298. Dzobo, K.; Senthebane, D.A.; Rowe, A.; Thomford, N.E.; Mwapagha, L.M.; Al-Awwad, N.; Dandara, C.; Parker, M.I. Cancer stem cell hypothesis for therapeutic innovation in clinical oncology? Taking the root out, not chopping the leaf. Omics 2016, 20, 681-691.
299. Dzobo, K.; Senthebane, D.A.; Thomford, N.E.; Rowe, A.; Dandara, C.; Parker, M.I. Not everyone fits the mold: Intratumor and intertumor heterogeneity and innovative cancer drug design and development. Omics 2018, 22, 17-34.
300. Baselga, J.; Cortes, J.; Kim, S.B.; Im, S.A.; Hegg, R.; Im, Y.H.; Roman, L.; Pedrini, J.L.; Pienkowski, T.; Knott, A.; et al. Pertuzumab plus trastuzumab plus docetaxel for metastatic breast cancer. N. Engl. J. Med. 2012, 366, 109-119.
301. Kawajiri, H.; Takashima, T.; Kashiwagi, S.; Noda, S.; Onoda, N.; Hirakawa, K. Pertuzumab in combination with trastuzumab and docetaxel for HER2-positive metastatic breast cancer. Expert Rev. Anticancer Ther. 2015, 15, 17-26.
302. Swain, S.M.; Baselga, J.; Kim, S.B.; Ro, J.; Semiglazov, V.; Campone, M.; Ciruelos, E.; Ferrero, J.M.; Schneeweiss, A.; Heeson, S.; et al. Pertuzumab, trastuzumab, and docetaxel in HER2-positive metastatic breast cancer. N. Engl. J. Med. 2015, 372, 724-734.
303. Swain, S.M.; Baselga, J.; Miles, D.; Im, Y.H.; Quah, C.; Lee, L.F.; Cortes, J. Incidence of central nervous system metastases in patients with HER2-positive metastatic breast cancer treated with pertuzumab, trastuzumab, and docetaxel: Results from the randomized phase iii study cleopatra. Ann. Oncol. 2014, 25, 1116-1121.
304. Swain, S.M.; Kim, S.B.; Cortes, J.; Ro, J.; Semiglazov, V.; Campone, M.; Ciruelos, E.; Ferrero, J.M.; Schneeweiss, A.; Knott, A.; et al. Pertuzumab, trastuzumab, and docetaxel for HER2-positive metastatic breast cancer (cleopatra study): Overall survival results from a randomised, double-blind, placebo-controlled, phase 3 study. Lancet Oncol. 2013, 14, 461-471.
305. National Academy of Sciences (US). The national academies collection: Reports funded by national institutes of health. In Toward PrecisionMedicine: Building a Knowledge Network for Biomedical Research and a New Taxonomy of Disease; National Academies Press (US), National Academy of Sciences: Washington, DC, USA, 2011.
306. Debouck, C. Integrating genomics across drug discovery and development. Toxicol. Lett. 2009, 186, 9-12.
307. Debouck, C.; Metcalf, B. The impact of genomics on drug discovery. Ann. Rev. Pharmacol. Toxicol. 2000, 40, 193-207.